Identification of a class of potent USP25/28 inhibitors with broad-spectrum anti-cancer activity

  • Signal Transduct Target Ther. 2022 Dec 8;7(1):393. doi: 10.1038/s41392-022-01209-2.
Jin Peng  #  1 ,  Kun Jiang  #  2 ,  Xiao Sun  1 ,  Lingzhi Wu  1 ,  Jiewei Wang  2 ,  Xiaomei Xi  3 ,  Xu Tan  4 ,  Tingbo Liang  5 ,  Changheng Tan  6 ,  Pumin Zhang  7
Affiliations
  • 1. Zhejiang Provincial Key Laboratory of Pancreatic Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310003, China.
  • 2. Shanghai Institute of Materia Medica, Shanghai, 200216, China.
  • 3. Chaser Therapeutics, Inc., Hangzhou, Zhejiang Province, 310018, China.
  • 4. Beijing Advanced Innovation Center for Structural Biology, School of Pharmaceutical Sciences, Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China.
  • 5. Zhejiang Provincial Key Laboratory of Pancreatic Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310003, China. [email protected].
  • 6. Shanghai Institute of Materia Medica, Shanghai, 200216, China. [email protected].
  • 7. Zhejiang Provincial Key Laboratory of Pancreatic Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310003, China. [email protected].
  • # Contributed equally.
PMID: 36481755 DOI: 10.1038/s41392-022-01209-2
Products